| Summary: | Emtricitabine/tenofovir alafenamide fumarate (FTC/TAF) (200 mg/10 mg and 200 mg/25 mg) is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) indicated for use in combination with other antiretroviral therapies (ARTs) for the treatment of HIV type 1 infection in adults and pediatric patients 12 years of age and older (and weighing ≥ 35 kg). It is available as 200 mg/10 mg and 200 mg/25 mg film-coated tablets; the recommended dose is one 200 mg/10 mg tablet daily when used in combination with a ritonavir‐ or cobicistat (COBI)-boosted protease inhibitor. Otherwise, the recommended dose is one 200 mg/25 mg tablet daily. The manufacturer submitted a price of $28.57 per tablet regardless of strength, which is slightly lower (by $0.51) than the unit cost of FTC/tenofovir disoproxil fumarate (TDF), the backbone component that FTC/TAF is expected to replace. The manufacturer is requesting that FTC/TAF be listed in combination with other ARTs for treatment of treatment‐naive and virologically suppressed HIV-1 infected adult and pediatric patients 12 years of age and older
|
|---|